계명대학교 의학도서관 Repository

Usefulness of baseline statin therapy in nonobstructive coronary artery disease by coronary computed tomographic angiography: From the CONFIRM (Coronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) study

Metadata Downloads
Author(s)
Yun-Kyeong ChoChang-Wook NamBon-Kwon KooJoshua Schulman-MarcusBrı´ainO´ . HartaighHeidi GransarYao LuStephan AchenbachMouaz Al-MallahDaniele AndreiniJeroen J. BaxMatthew J. BudoffFilippo Cademartiri1Tracy Q. CallisterHyuk-Jae ChangKavitha ChinnaiyanBenjamin J. W. ChowRicardo C. CuryAugustin DelagoGudrun FeuchtnerMartin HadamitzkyJo¨ rg HausleiterPhilipp A. KaufmannYong-Jin KimJonathon LeipsicErica MaffeiHugo MarquesGianluca PontoneGilbert L. RaffRonen RubinshteinLeslee J. ShawTodd C. VillinesDaniel S. BermanErica C. JonesJessica M. PeñaFay Y. LinJames K. Min
Keimyung Author(s)
Cho, Yun KyeongNam, Chang Wook
Department
Dept. of Internal Medicine (내과학)
Journal Title
PLoS One
Issued Date
2018
Volume
13
Issue
12
Abstract
Background
The extent to which the presence and extent of subclinical atherosclerosis by coronary computed tomography angiography influences a potential mortality benefit of statin is unknown. We evaluated the relationship between statin therapy, mortality, and subclinical atherosclerosis.

Methods
In the CONFIRM study, patients with normal or non-obstructive plaque (<50% diameter stenosis) for whom data on baseline statin use was available were included. Coronary artery calcium (CAC) was quantified using the Agatston score. The extent of non-obstructive coronary atherosclerosis was quantified using the segment involvement score (SIS). 8,016 patients were followed for a median of 2.5 years with analysis of all-cause mortality and major adverse cardiac events (MACE) including all-cause mortality, myocardial infarction, unstable angina, target vessel revascularization, and coronary artery disease-related hospitalization.

Results
1.2% of patients experienced all-cause mortality. Patients not on baseline statin therapy had a stepwise increased risk of all-cause mortality by CAC (relative to CAC = 0; CAC 1–99: hazard ratio [HR] 1.65, CAC 100–299: HR 2.19, and CAC≥300: HR 2.98) or SIS (relative to SIS = 0; SIS 1: HR 1.62, SIS 2–3: 2.48 and SIS≥4: 2.95). Conversely, in patients on baseline statin therapy, there was no significant increase in mortality risk with increasing CAC (p value for interaction = 0.049) or SIS (p value for interaction = 0.007). The incidence of MACE was 2.1%. Similar to the all-cause mortality, the risk of MACE was increased with CAC or SIS strata in patient not on baseline statin therapy. However, this relation was not observed in patient on baseline statin therapy.

Conclusion
In individuals with non-obstructive coronary artery disease, increased risk of adverse events occurs with increasing CAC or SIS who are not on baseline statin therapy. Statin therapy is associated with a mitigation of risk of cardiac events in the presence of increasing atherosclerosis, with no particular threshold of disease burden.
Keimyung Author(s)(Kor)
조윤경
남창욱
Publisher
School of Medicine (의과대학)
Citation
Yun-Kyeong Cho et al. (2018). Usefulness of baseline statin therapy in nonobstructive coronary artery disease by coronary computed tomographic angiography: From the CONFIRM (Coronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) study. PLoS One, 13(12), e0207194–e0207194. doi: 10.1371/journal.pone.0207194
Type
Article
ISSN
1932-6203
Source
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0207194
DOI
10.1371/journal.pone.0207194
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41841
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.